Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-22 Phase 1 high dose study
NCT04503863Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of scopolamine in sialorrhea (3 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Adverse events, Body temperature and 4 more. Started Jul 2020; status: completed.
02
Drugs
scopolamine
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT04503863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503863.